UNIVERSITY OF CONNECTICUT

Their core work

The University of Connecticut is a major US public research university that contributes specialist expertise to European research collaborations, exclusively as a third-party partner under MSCA mobility schemes. Their H2020 involvement spans two distinct domains: biomedical research — particularly neurodegenerative disease diagnostics and neural cell biology — and high-energy nuclear/particle physics. UConn serves as a transatlantic knowledge bridge, enabling EU-funded researchers to access American laboratory infrastructure and scientific expertise in these highly specialized fields.

What they specialise in

How they've shifted over time

UConn's early H2020 involvement (2017–2018) centered on biomedical topics — wearable health monitors and neuroscience tools for diagnosing diseases like ALS using immunoglobulin screening and electrophysiology techniques. By 2019, participation shifted to include fundamental physics, with projects on quantum chromodynamics and heavy ion collisions at major particle accelerators. This reflects the breadth of a large research university rather than a single-track evolution, but it does show growing engagement with large-scale international physics collaborations.

UConn's recent projects suggest growing involvement in large-scale international physics experiments, making them a relevant partner for future accelerator-based or Electron Ion Collider research collaborations.

How they like to work

UConn participates exclusively as a third-party entity — never as coordinator or direct consortium partner — which is typical for non-EU institutions in MSCA mobility programs. They connect to 13 unique partners across 10 countries, indicating broad but lightweight engagement. This role suggests they provide specialized lab access and mentorship for visiting researchers rather than driving project governance or deliverables.

Connected to 13 partners across 10 countries, reflecting the global mobility nature of MSCA schemes. Their network spans multiple continents, anchoring transatlantic research exchanges between US facilities and European institutions.

What sets them apart

As a US-based third party, UConn offers European researchers access to American infrastructure that is otherwise difficult to include in H2020 consortia — from neuroscience labs with advanced electrophysiology setups to proximity to Brookhaven National Laboratory and the future Electron Ion Collider. For consortium builders, UConn brings credibility and facilities without requiring direct EU funding allocation, since third-party costs are handled differently. Their dual strength in life sciences and fundamental physics is unusual and valuable for multidisciplinary proposals.

Highlights from their portfolio

• AUTOIGG
  Combines automated immunoglobulin screening with advanced electrophysiology techniques (voltage-sensitive dyes, MEA) for ALS diagnostics — a technically rich and medically significant project.
• HIEIC
  Connects UConn to three major particle accelerator programs (LHC, RHIC, Electron Ion Collider), positioning them at the frontier of nuclear physics research.